However, most randomized clinical trials have confirmed that PD-L1 expression remains only moderately predictive, being dynamic, heterogeneous, and unable to distinguish adaptive and constitutive patterns of expression and neglecting variable characteristics of the tumor immune microenvironment (Chan et al., 2019). The gene discussed is CD274; the disease is neoplasm.